Directly targeting transcriptional dysregulation in cancer

Nature Reviews Cancer

Volumn 15, Issue 11, 2015, Pages 686-694

  Gonda, Thomas J ^a   Ramsay, Robert G ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE THREONINE KINASE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

DNA METHYLATION; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HUMAN; INTRACELLULAR SIGNALING; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSCRIPTION REGULATION; TREATMENT FAILURE; TUMOR GROWTH; WNT SIGNALING PATHWAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84944906185     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc4018     Document Type: Review

References (120)

1. Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet. 9, 138-141 (1993).
2. Berger, N. A. et al. Cancer in the elderly. Trans. Am. Clin. Climatol. Assoc. 117, 147-156 (2006).
3. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
4. Giuriato, S., Rabin, K., Fan, A. C., Shachaf, C. M. & Felsher, D. W. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin. Cancer Biol. 14, 3-11 (2004).
5. Felsher, D. W. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 68, 3081-3086 (2008).
6. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457 (2006).
7. Orwell, G. Animal Farm (Penguin Group 1946).
8. Fojo, T., Mailankody, S. & Lo, A. Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol. Head Neck Surg. 140, 1225-1236 (2014).
9. Hartsough, E., Shao, Y. & Aplin, A. E. Resistance to RAF inhibitors revisited. J. Invest. Dermatol. 134, 319-325 (2014).
10. Kwong, L. N. & Davies, M. A. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene 33, 1-9 (2014).
11. Bishop, J. M. Molecular themes in oncogenesis. Cell 64, 235-248 (1991).
12. García-Escudero, R. & Paramio, J.M. Gene expression profiling as a tool for basic analysis and clinical application of human cancer. Mol. Carcinog. 47, 573-579 (2008).
13. Bennicelli, J. L., Edwards, R. H. & Barr, F. G. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 93, 5455-5459 (1996).
14. Meyer, C. et al. The MLL recombinome of acute leukemias in 2013. Leukemia 27, 2165-2176 (2013).
15. Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233-245 (2007).
16. Peter, M. et al. An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumor. Int. J. Cancer 67, 339-342 (1996).
17. Sorensen, P. H. & Triche, T. J. Gene fusions encoding chimaeric transcription factors in solid tumours. Semin. Cancer Biol. 7, 3-14 (1996).
18. Nambiar, M., Kari, V. & Raghavan, S. C. Chromosomal translocations in cancer. Biochim. Biophys. Acta 1786, 139-152 (2008).
19. Simó-Riudalbas, L. & Esteller, M. Cancer genomics identifies disrupted epigenetic genes. Hum. Genet. 133, 713-725 (2014).
20. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
21. Cucco, F. et al. Mutant cohesin drives chromosomal instability in early colorectal adenomas. Hum. Mol. Genet. 23, 6773-6778 (2014).
22. Solomon, D. A., Kim, J. S. & Waldman, T. Cohesin gene mutations in tumorigenesis: from discovery to clinical significance. BMB Rep. 47, 299-310 (2014).
23. Bojesen, S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371-384 (2013).
24. Nickerson, M. L. et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin. Cancer Res. 20, 4935-4948 (2014).
25. Griewank, K. G. et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J. Natl Cancer Inst. 106, doi: 10.1093/jnci/dju246 (2014).
26. Mansour, M. R. et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014).
27. Vicente-Dueñas, C., Romero-Camarero, I., Cobaleda, C. & Sánchez-García, I. Function of oncogenes in cancer development: a changing paradigm. EMBO J. 32, 1502-1513 (2013).
28. Burke, J. M. Dx/Rx: Leukemia. Dx/Rx Oncology Series 1-11 (Jones and Bartlett, 2012).
29. Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56-67 (2012).
30. Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628-1640 (2011).
31. Germann, M. et al. Tripartite interactions between Wnt signaling, Notch and Myb for stem/progenitor cell functions during intestinal tumorigenesis. Stem Cell Res. 13, 355-366 (2014).
32. Rowley, J. D. Chromosomes in leukemia and beyond: from irrelevant to central players. Annu. Rev. Genom. Hum. Genet. 10, 1-18 (2009).
33. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
34. Miyamoto, T., Weissman, I. L. & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl Acad. Sci. USA 97, 7521-7526 (2000).
35. Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014).
36. Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548-2553 (2014).
37. Corces-Zimmerman, M. R. & Majeti, R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia 28, 2276-2282 (2014).
38. Clevers, H. & Nusse, R. Wnt/β-catenin signaling and disease. Cell 149, 1192-1205 (2012).
39. Morin, P. J. et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790 (1997).
40. Walther, A. et al. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 9, 489-499 (2009).
41. Xu, H. et al. Cohesin Rad21 mediates LOH and is up-regulated via Wnt promoting transcriptional dysregulation in GI tumors. Cell Rep. 9, 1781-1797 (2014).
42. Gasi Tandefelt, D., Boormans, J., Hermans, K. & Trapman, J. ETS fusion genes in prostate cancer. Endocr. Relat. Cancer 21, R143-R152 (2014).
43. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
44. Tao, J. et al. Notch activation as a driver of osteogenic sarcoma. Cancer Cell 26, 390-401 (2014).
45. Ranganathan, P., Weaver, K. L. & Capobianco, A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 11, 338-351 (2011).
46. Schleiermacher, G., Janoueix-Lerosey, I. & Delattre, O. Recent insights into the biology of neuroblastoma. Int. J. Cancer 135, 2249-2261 (2014).
47. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121-1124 (1984).
48. D'Alfonso, T. M. et al. MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. Hum. Pathol. 45, 2270-2280 (2014).
49. Mitani, Y. et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin. Cancer Res. 16, 4722-4731 (2010).
50. Persson, M. et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl Acad. Sci. USA 106, 18740-18744 (2009).
51. French, C. A. The importance of diagnosing NUT midline carcinoma. Head Neck Pathol. 7, 11-16 (2013).
52. French, C. A. Pathogenesis of NUT midline carcinoma. Annu. Rev. Pathol. 7, 247-265 (2012).
53. Yamamoto, S. et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 25, 762-777 (2014).
54. Sodir, N. M. & Evan, G. I. Finding cancer's weakest link. Oncotarget 2, 1307-1313 (2011).
55. Pattabiraman, D. R. & Gonda, T. J. Role and potential for therapeutic targeting of MYB in leukemia. Leukemia 27, 269-277 (2013).
56. Jin, S. et al. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Invest. 120, 593-606 (2010).
57. Pattabiraman, D. R. et al. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood 123, 2682-2690 (2014).
58. Ramsay, R. G. & Gonda, T. J. MYB function in normal and cancer cells. Nat. Rev. Cancer 8, 523-534 (2008).
59. Miao, R. Y. et al. MYB is essential for mammary tumorigenesis. Cancer Res. 71, 7029-7037 (2011).
60. Shi, J. & Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728-736 (2014).
61. Thomas, S. J., Snowden, J. A., Zeidler, M. P. & Danson, S. J. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 113, 365-371 (2015).
62. Perkins, N. D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 12, 121-132 (2012).
63. Gonnissen, A., Isebaert, S. & Haustermans, K. Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget 6, 13899-13913 (2015).
64. Bewry, N. N. et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol. Cancer Ther. 7, 3169-3175 (2008).
65. Haferlach, T., Bacher, U., Kern, W., Schnittger, S. & Haferlach, C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann. Hematol. 87, 1-10 (2008).
66. Serinsöz, E. et al. Aberrant expression of β-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br. J. Haematol. 126, 313-319 (2004).
67. Charbel, C. et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J. Invest. Dermatol. 134, 1067-1074 (2014).
68. Tschandl, P. et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS ONE 8, e69639 (2013).
69. Ceol, C. J. et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517 (2011).
70. Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477-2478 (2014).
71. Lackner, M. R., Wilson, T. R. & Settleman, J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 8, 999-1014 (2012).
72. Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
73. Solit, D. B. & Rosen, N. Towards a unified model of RAF inhibitor resistance. Cancer Discov. 4, 27-30 (2014).
74. Wang, S. E. et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10, 25-38 (2006).
75. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
76. Sos, M. L. et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256-3261 (2009).
77. Meyer, S. C. & Levine, R. L. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin. Cancer Res. 20, 2051-2059 (2014).
78. Nasr, R. et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 14, 1333-1342 (2008).
79. Grimwade, D., Mistry, A. R., Solomon, E. & Guidez, F. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat. Res. 145, 219-235 (2010).
80. Hu, J. et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 106, 3342-3347 (2009).
81. Stegle, O., Teichmann, S. A. & Marioni, J. C. Computational and analytical challenges in single-cell transcriptomics. Nat. Rev. Genet. 16, 133-145 (2015).
82. Berg, T. et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 99, 3830-3835 (2002).
83. Harvey, S. R. et al. Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. J. Am. Chem. Soc. 134, 19384-19392 (2012).
84. Müller, I. et al. Targeting of the MYCN protein with small molecule c-MYC inhibitors. PLoS ONE 9, e97285 (2014).
85. Pellegrino, S. et al. Molecular insights into dimerization inhibition of c-Maf transcription factor. Biochim. Biophys. Acta 1844, 2108-2115 (2014).
86. Fung, S. M., Ramsay, G. & Katzen, A. L. MYB and CBP: physiological relevance of a biochemical interaction. Mech. Dev. 120, 711-720 (2003).
87. Oelgeschläger, M., Janknecht, R., Krieg, J., Schreek, S. & Lüscher, B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J. 15, 2771-2780 (1996).
88. Sampurno, S. et al. The Myb-p300-CREB axis modulates intestine homeostasis, radiosensitivity and tumorigenesis. Cell Death Dis. 4, e605 (2013).
89. Grossmann, T. N. et al. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc. Natl Acad. Sci. USA 109, 17942-17947 (2012).
90. Uttarkar, S. et al. Naphthol AS-E phosphate inhibits the activity of the transcription factor Myb by blocking the interaction with the KIX domain of the coactivator p300. Mol. Cancer Ther. 14, 1276-1285 (2015).
91. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
92. Clausen, D. M. et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J. Pharmacol. Exp. Ther. 335, 715-727 (2010).
93. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480-488 (2013).
94. Griffiths, E. A. & Gore, S. D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin. Hematol. 45, 23-30 (2008).
95. Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202 (2001).
96. Marks, P. A., Sheffery, M., Ramsay, R., Ikeda, K. & Rifkind, R. A. Induction of transformed cells to terminal differentiation. Ann. NY Acad. Sci. 511, 246-255 (1987).
97. Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017-1025 (2013).
98. Liu, W., Deng, L., Song, Y. & Redell, M. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS ONE 9, e98270 (2014).
99. Davis, M. I. et al. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J. Biol. Chem. 289, 13717-13725 (2014).
100. Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630 (2013).
101. Wyce, A. et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 8, e72967 (2013).
102. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
103. Roe, J. S., Mercan, F., Rivera, K., Pappin, D. J. & Vakoc, C. R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol. Cell 58, 1028-1039 (2015).
104. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
105. Dolan, D. E. & Gupta, S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 21, 231-237 (2014).
106. Naidoo, J., Page, D. B. & Wolchok, J. D. Immune modulation for cancer therapy. Br. J. Cancer 111, 2214-2219 (2014).
107. Carpinteri, S. et al. Optimizing DNA vaccines against nuclear oncogenes. ImmunoGastroenterol. 1, 108-118 (2012).
108. Williams, B. B. et al. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol. Immunother. 57, 1635-1645 (2008).
109. Cross, R. S. et al. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin. Transl Immunol. 4, e30 (2015).
110. Fuqua, S. A., Gu, G. & Rechoum, Y. Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res. Treat. 144, 11-19 (2014).
111. Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538-542 (2015).
112. Gabay, M., Li, Y. & Felsher, D. W. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb. Perspect. Med. 4, a014241 (2014).
113. Pereira, L. A. et al. MYB elongation is regulated by the nucleic acid binding of NFκB p50 to the intronic stem-loop region. PLoS ONE 10, e0122919 (2015).
114. Mitra, P., Pereira, L. A., Drabsch, Y., Ramsay, R. G. & Gonda, T. J. Estrogen receptor-α recruits P-TEFb to overcome transcriptional pausing in intron 1 of the MYB gene. Nucleic Acids Res. 40, 5988-6000 (2012).
115. Marks, P. A. & Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84-90 (2007).
116. Cross, R. S. et al. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin. Transl Immunol. 4, e30 (2015).
117. Copeland, A., Buglio, D. & Younes, A. Histone deacetylase inhibitors in lymphoma. Curr. Opin. Oncol. 22, 431-436 (2010).
118. Yardley, D. A. et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128-2135 (2013).
119. Chen, C. W. et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21, 335-343 (2015).
120. Purow, B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 727, 305-319 (2012).